Valuein

Overview

STERIS plc

STENYSEHealth CareOrthopedic, Prosthetic & Surgical Appliances & SuppliesCIK 0001757898Large-cap benchmark

Latest 10-K: FY2026, filed May 29, 2026 · Open the 10-K (Inline XBRL) ↗

Revenue
$5.94B
8.7%YoYup from FY2025
TotalRevenue
Gross profit
$2.63B
9.3%YoYup from FY2025
GrossProfit
Operating income
$1.10B
27.1%YoYup from FY2025
OperatingIncome
Net income
$0.78B
27.3%YoYup from FY2025
NetIncome
Diluted EPS
$7.93
27.9%YoYup from FY2025
EPSDiluted
Diluted shares
98.7M
0.4%YoYdown from FY2025
WeightedAvgSharesDiluted

At a glance

Growth

  • STERIS plc reported revenue of $5.94B for fiscal 2026, up 8.7% from fiscal 2025.
  • Revenue grew faster than the median S&P 500 member in 3 of the last 4 fiscal years.

Profitability

  • Operating margin was 18.6% and net margin was 13.2%.

Per share

  • Diluted EPS was $7.93, up 27.9% from the prior year.
Loading insider and institutional summary

Written from the filed figures on this page by fixed rules — no AI.

Data as of Oct 31, 2026 · Sources: SEC EDGAR 10-K

Financial statements

Annual figures from the 10-K, most recent fiscal year first.

Income Statement

5 annual periods

Chip: YoY change.

Income Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line itemFY2026FY2025FY2024FY2023FY20224Y CAGR
Revenue
$5.94B8.7%up
$5.46B6.2%up
Benchmark median 6.4%
$5.14B13.3%up
Benchmark median 4.5%
$4.54B7.4%up
Benchmark median 4.8%
$4.22B35.9%up
Benchmark median 10.3%
8.9%
Gross Profit
Median of 315 / 498
$2.63B9.3%up
$2.40B8.3%up
Benchmark median 6.8%
$2.22B12.0%up
Benchmark median 5.5%
$1.98B5.2%up
Benchmark median 5.2%
$1.88B40.2%up
Benchmark median 8.3%
8.7%
Operating Income
Median of 373 / 498
$1.10B27.1%up
$0.87B3.6%up
Benchmark median 7.3%
$0.84B5.7%up
Benchmark median 7.4%
$0.79B65.6%up
Benchmark median 4.9%
$0.48B12.9%down
Benchmark median 7.5%
23.2%
Net Income
$782.30M27.3%up
$614.60M62.5%up
Benchmark median 4.8%
$378.20M253.4%up
Benchmark median 5.7%
$107.03M56.1%down
Benchmark median 1.9%
$243.89M38.6%down
Benchmark median 1.3%
33.8%
EPS (Diluted)
$7.9327.9%up
$6.2062.7%up
Benchmark median 6.2%
$3.81256.1%up
Benchmark median 7.9%
$1.0756.9%down
Benchmark median 1.9%
$2.4846.4%down
Benchmark median 1.5%
33.7%

Balance Sheet

5 annual periods

Chip: YoY change.

Balance Sheet, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line itemFY2026FY2025FY2024FY2023FY20224Y CAGR
Total Assets
$10.74B5.8%up
$10.15B8.3%down
Benchmark median 5.6%
$11.06B2.2%up
Benchmark median 3.4%
$10.82B5.3%down
Benchmark median 4.1%
$11.42B73.8%up
Benchmark median 2.2%
-1.5%
Total Liabilities
Median of 357 / 498
$3.54B0.3%up
$3.53B25.6%down
Benchmark median 6.4%
$4.75B0.3%up
Benchmark median 1.9%
$4.73B3.0%down
Benchmark median 2.9%
$4.88B81.8%up
Benchmark median 2.0%
-7.7%
Stockholders' Equity
$7.20B8.8%up
$6.62B4.8%up
Benchmark median 6.8%
$6.32B3.7%up
Benchmark median 5.4%
$6.09B7.0%down
Benchmark median 7.3%
$6.54B68.2%up
Benchmark median 2.5%
2.4%
Cash & Equivalents
—
—
—
—
—
—
Total Debt
$1.93B5.5%down
$2.04B36.3%down
Benchmark median 2.1%
$3.21B4.1%up
Benchmark median 0.2%
$3.08B0.3%down
Benchmark median 0.3%
$3.09B87.1%up
Benchmark median 0.1%
-11.1%

Cash Flow Statement

5 annual periods

Chip: YoY change.

Cash Flow Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line itemFY2026FY2025FY2024FY2023FY20224Y CAGR
Operating Cash Flow
$1.34B16.8%up
$1.15B18.0%up
Benchmark median 6.3%
$0.97B28.6%up
Benchmark median 4.8%
$0.76B10.5%up
Benchmark median 9.9%
$0.68B0.7%down
Benchmark median -0.7%
18.3%
Capital Expenditures
$369.00M0.3%down
$370.10M2.7%up
Benchmark median 5.4%
$360.30M0.5%down
Benchmark median 2.8%
$361.97M25.9%up
Benchmark median 11.3%
$287.56M20.2%up
Benchmark median 14.0%
6.4%
Free Cash Flow
Median of 378 / 498
$972.40M25.0%up
$778.00M26.9%up
Benchmark median 7.3%
$613.00M55.2%up
Benchmark median 6.1%
$394.98M0.6%down
Benchmark median 8.8%
$397.25M11.8%down
Benchmark median -11.3%
25.1%

n/m: not meaningful — the base (the prior year, or the first year for the CAGR) was zero or negative, or a per-share figure’s share basis changed (stock split). “—” means the figure is not available.

Benchmark median = median of the companies in the benchmark universe on Dec 31 of each fiscal year, from their own 10-K filings; a change counts only companies whose prior year was positive. Each median uses every member that reports the line item; where fewer than 80% do (banks and insurers file no gross profit), the row names how many. Published where at least 250 companies report it. Updated 2026-10-27. This compares reported figures, not share-price returns. Methodology

Ratios & valuation

FY2026

Every ratio read two ways: Wall Street’s popular formula and the value investor’s stricter one. Same question, same unit. Pick a ratio.

Valuation · Earnings yield

What a dollar of market value earned

3.6%

Wall Street

on net earnings

FY2025 2.7%

4.5%

Value investor

on free cash flow

FY2025 3.5%

Gap +0.9 pts: Value-investor figure 0.9 points higher

How it’s calculated

Wall Street · on net earnings

Diluted EPS ÷ fiscal-year-end share price (1 ÷ P/E)

pe_ratio (ratio table)

P/E 27.9×

Value investor · on free cash flow

(Operating cash flow − capital expenditures) ÷ market capitalisation (fiscal-year-end close × weighted-average diluted shares)

free cash flow ÷ market cap

Each ratio measures one thing two ways, in the same unit: the popular formula, then a stricter one, so a lower figure is the stricter reading. Gap = value-investor figure minus Wall Street figure, from the figures shown.

Price-based ratios use the fiscal-year-end closing price. Free cash flow = operating cash flow − capital expenditures (we compute it; filings rarely report it). n/m = not meaningful (denominator ≤ 0); “—” = not reported. Each ratio’s formulas are under “How it’s calculated”.

Loading capital allocation

Smart money

Loading insider and institutional activity

Showing the most recent 5 annual periods. Get longer history on the Pro plan, or the full history (1993–present) plus the smart-money dataset and webhooks on Institutional.

Peers, filings & research

Loading sector peers
Loading recent filings

Research Reports

No published research on STE yet.

Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on STE and publish the result to your public profile.

Loading the data behind this page

Cite this page

Data as of Oct 31, 2026. Canonical address: https://valuein.biz/data/STE

APA-style text
Valuein. (2026, October 31). STERIS plc (STE) financial statements, earnings power and smart-money summary [Data set]. Source: SEC EDGAR filings. https://valuein.biz/data/STE
BibTeX
@misc{valuein_ste_2026,
  author = {{Valuein}},
  title = {STERIS plc (STE) financial statements, earnings power and smart-money summary},
  year = {2026},
  howpublished = {\url{https://valuein.biz/data/STE}},
  note = {Data as of 2026-10-31; source: SEC EDGAR filings}
}
Open 10-K in SEC Inline XBRL viewer

10-K filed May 29, 2026 · accession 0001628280-26-039136

Agents: every figure Valuein's tools return carries a fact_id that traces to its SEC filing.

point-in-time · survivorship-free · every number traceable to its SEC filing

Index names are trademarks of their owners; Valuein is not affiliated with or endorsed by any index provider.